Publications of Research Area C


Gemcitabine/Abraxane treatment monitoring by 3D bSSFP imaging with hyperpolarized [1-13C]pyruvate in a murine endogenous model of PDAC

Anna-Maria Schmidmüller1, Irina Heid1, Jason G. Skinner2, Geoffrey J. Topping2, Katja Steiger3,5, Simon Baller1, Wolfgang Gottwald2, Franz Schilling2, Rickmer Braren1,4 Link to the paper

Contrast agent-free diffusion weighted- MRI and T1/2 mapping for therapy response monitoring in murine pancreatic ductal adenocarcinoma (PDAC)

Simon Baller1, Irina Heid1, Geoffrey J. Topping2, Katja Steiger3,4, Anna-Maria Schmidmüller2, Felix Harder1, Franz Schilling2, Rickmer Braren1,5 Link to the paper

Hyperpolarized [1-13C] pyruvate Magnetic Resonance Spectroscopic Imaging (MRSl) identifies pancreatic cancer subtypes in mice

Irina Heid1, Moritz Mayer1, Katja Peschke2, Geoffrey J. Topping3, Katja Steiger1, Martin Grashei3, Maximilian Aigner3, Marija Trajkovic-Arsic5, Maximilian Reichert2, Franz Schilling3, Rickmer Braren1,6 Link to the paper

Hypoxia imaging-guided mesenchymal stem cell-mediated sodium iodide symporter (NIS) gene delivery in glioblastoma

Carolin Kitzberger1, Martin Grashei2, Katja Steiger3, Rim S J Sarker 3, Rainer Glaß4, Wolfgang Weber2, Peter J Nelson1, Franz Schilling2, Christine Spitzweg1,5

Link to the paper

TNF-A RESPECIFIES HUMAN MESENCHYMAL STEM CELLS TO A NEURAL FATE AND PROMOTES MIGRATION TOWARD EXPERIMENTAL GLIOMA

V Egea, L von Baumgarten, C Schichor, B Berninger, T Popp, P Neth, R Goldbrunner, Y Kienast, F Winkler, M Jochum and C Ries. (03-12-2010). Cell Death and Differentiation advance online publication, 2010

EFEMP1 AND P27 KIP1 MODULATE RESPONSIVENESS OF PANCREATIC CANCER CELLS TOWARDS A DUAL PI3K/MTOR INHIBITOR IN PRECLINICAL MODELS

Sandra Diersch, Patrick Wenzel, Melanie Szameitat, Philipp Eser, Mariel C. Paul, Barbara Seidler, Stefan Eser, Marlena Messer, Maximilian Reichert, Philipp Pagel, Irene Esposito, Roland M. Schmid, Dieter Saur, Günter Schneider. (26-02-2013). Impact Journals, 2013, Vol. 4, No 2, 277-288

[18F]FLT IS SUPERIOR TO [18F]FDG FOR PREDICTING EARLY RESPONSE TO ANTIPORLIFERATIVE TREATMENT IN HIGH-GRADE LYMPHOMA IN A DOSE-DEPENDENT MANNER

Nicolas Graf, Ken Herrmann, Barbara Numberger, Daniela Zwisler, Michaela Aichler, Annette Feuchtinger, Tibor Schuster, Hans-Jürgen Wester, Reingard Senekowitsch-Schmidtke, Christian Peschel, Markus Schwaiger, Ulrich Keller, Tobias Dechow, Andreas K. Buck. (05-10-2012). Springer Link, 2012, 40:34–43, Eur J Nucl Med Mol Imaging

FLT-PET IS SUPERIOR TO FDG-PET FOR VERY EARLY RESPONSE PREDICTION IN NPM-ALK-POSITIVE LYMPHOMA TREATED WITH TARGETED THERAPY

Li Z, Graf NA, Herrmann K, Jünger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, Schwaiger M, Buck A, Keller U, Dechow T. (08-08-2012). Cancer Res, 2012

DISCLOSURE OF ERLOTINIB AS A MULTIKINASE INHIBITOR IN PANCREATIC DUCTAL ADENOCARCINOMA

Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, Saur D, Schneider G. (01-11-2011). Neoplasia., 2011, 13(11), 1026-34

ASSESSING ANTIANGIOGENIC THERAPY RESPONSE BY DCE-MRI: DEVELOPMENT OF A PHYSIOLOGY DRIVEN MULTI-COMPARTMENT MODEL USING POPULATION PHARMACOMETRICS

Steingoetter A, Menne D, Braren RF. (18-10-2011). PLoS One., 2011, 6(10), e26366